Compare LAZ & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAZ | ACAD |
|---|---|---|
| Founded | 1848 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2004 | 2000 |
| Metric | LAZ | ACAD |
|---|---|---|
| Price | $50.34 | $21.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $52.75 | $30.55 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | 2.17 | ★ 2.30 |
| Revenue | ★ $3,186,466,000.00 | $726,437,000.00 |
| Revenue This Year | $14.52 | $18.90 |
| Revenue Next Year | $13.08 | $11.62 |
| P/E Ratio | $23.09 | ★ $9.56 |
| Revenue Growth | 1.48 | ★ 40.45 |
| 52 Week Low | $33.45 | $14.08 |
| 52 Week High | $58.75 | $28.35 |
| Indicator | LAZ | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 69.32 | 48.71 |
| Support Level | $47.92 | $20.22 |
| Resistance Level | $52.41 | $22.03 |
| Average True Range (ATR) | 1.93 | 0.73 |
| MACD | 1.37 | 0.11 |
| Stochastic Oscillator | 100.00 | 55.86 |
Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.